The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma

Cancer

Volumn 83, Issue 5, 1998, Pages 918-924

  Ahuja, Vinita ^a   Edward Coleman, R ^b   Herndon, James ^b   Patz Jr , Edward F ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lung carcinoma; Positron emission tomography imaging; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 3543006512     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y     Document Type: Article

References (42)

1. Boring CC, Squires TS, Tong T. Cancer statistics - 1992. Cancer 1992;42:19-43.
2. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
3. Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the lung cancer study group. Cancer 1984;54:1802-13.
4. Lipford EH, Eggleston JC, Lillemoe KD, Sears DL, Moor GW, Baker RR. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol 1984;8:357-65.
5. Pater JL, Loeb M. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Cancer 1982;50:326-31.
6. Ichinose Y, Hara N, Ohta N, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? J Thorac Cardiovasc Surg 1993;106:90-4.
7. Harpole DH, Herndon JE, Young WG, Wolfe WG, Sabiston DC. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76:787-96.
8. Naruke T, Goya T, Tsuchiyar, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-7.
9. Filderman AE, Silvestri GA, Gatsonis C, Luthringer DJ, Honig J, Flynn SD. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. Am Rev Respir Dis 1992;146:707-10.
10. Graziano SL. Non-small cell lung cancer clinical value of new biological predictors. Lung Cancer 1997;17:S37-58.
11. Johnson B. Biologic and molecular prognostic factors - impact on treatment of patients with non-small cell lung cancer. Chest 1995;107:287S-90S.
12. Geddes DM. The natural history of lung cancer: a review based on rates of tumor growth. Br J Dis Chest 1979;73:1-17.
13. Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. AJR 1956;76:988-1000.
14. Nathan MH, Collins VP, Adams RA. Differentiation of benign and malignant pulmonary nodules by growth rate. Radiology 1962;79:221-32.
15. Nathan MH. Management of solitary pulmonary nodules: an organized approach based on growth rate statistics. JAMA 1974;227:1141-4.
16. Duhaylongsod FG, Lowe VJ, Patz EF Jr., Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348-52.
17. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
18. Harnacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
19. Strauss GM, Gleason RE, Sugarbaker DJ. Screening for lung cancer. Another look; a different view. Chest 1997;111:754-68.
20. Isobe H, Miyamoto H, Shimizu T, et al. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer 1990;65:1391-5.
21. Zimmerman PV, Bint MH, Hawson GAT, Parsons PG. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet 1987;2(8558):530-3.
22. Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-5.
23. Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen A - a favorable prognostic factor in non-small cell lung cancer. N Engl J Med 1991;324:1084-90.
24. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993;53:1-4.
25. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 1995;13:1221-30.
26. Macchiarini P, Fontanini G, Hardin MJ, et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1NOMO non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993;106:80-9.
27. Dresler CN, Ritter JH, Wick MR, Roper CL, Patterson GA, Cooper JD. Immunostains for blood group antigens lack prognostic significance in T1 lung carcinoma. Ann Thorac Surg 1995;59:1069-73.
28. Lee JS, Hong WK. Prognostic factors in lung cancer. N Engl J Med 1992;327:47-8.
29. Steele JD, Buell P. Asymptomatic solitary pulmonary nodules: host survival, tumor size and growth rate. J Thorac Cardiovasc Surg 1973;65:40-51.
30. Weiss W. Tumor doubling time and survival of men with bronchogenic carcinoma. Chest 1974;65:3-8.
31. Usuda K, Saito Y, Sagawa M, et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 1994;74:2239-44.
32. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut1 and Glut3 in stage 1 nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-51.
33. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487-90.
34. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Chest 1993;104:997-1002.
35. Gupta NC, Frank AR, Dewan NA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992;184:441-4.
36. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET. Chest 1996;109:982-8.
37. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573-82.
38. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-7.
39. Scott WJ, Schwabe JL, Gupta NC, Dewan NA, Reeb SD, Sugimoto JT. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F] fluorodeoxyglucose. Ann Thorac Surg 1994;58:698-703.
40. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: are inflammatory cells important? J Nucl Med 1995;36:1854-61.
41. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.
42. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301-6.